金斯瑞生物科技(01548.HK)骨髓瘤药初始安全性和有效性於中美研究结果一致
金斯瑞生物科技(01548.HK)公布,评估JNJ-68284528 (JNJ-4528)有效性及安全性的Ib/II期CARTITUDE-1研究的初始结果,将於12月9日於美国佛罗里达州奥兰多举行的美国血液学会2019年年会上的口头汇报中进行报告。根据美国CARTITUDE-1研究结果显示,公司观察到其初始安全性和有效性资料与中国LEGEND-2研究一致。
JNJ-4528为一种正在进行评价的治疗复发或难治性多发性骨髓瘤患者的研究性靶向B细胞成熟抗原(BCMA)的嵌合抗原受体T细胞(CAR-T)疗法。
此外,公司附属Legend Biotech,
USA Inc.和Legend Biotech Ireland Limited与Janssen签订一项全球合作和授权合约,共同开发和商业化治疗多发性骨髓瘤的LCAR-B38M/JNJ4828。
LCARB38M/JNJ-4528是一种结构新颖的CAR-T细胞疗法,含有4-1BB共刺激结构域和两个靶向BCMA的单域抗体,旨在增加抗体亲和力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.